{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-262264","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2026-06-08T22:23:37+00:00","discovered_at":"2026-06-09T10:05:00.301680+00:00","generated_at":"2026-06-09T10:08:21.466256+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"AN2 Therapeutics stockholders elect three Class I directors and ratify auditor at 2026 annual meeting","bullets":["All three Class I director nominees elected: Kabeer Aziz (13.5M for, 4.0M withheld), Gilbert Marks (15.9M for), Rob Readnour (15.9M for).","Ratification of PricewaterhouseCoopers as auditor for fiscal 2026 approved with 22,724,674 for, 13 against, 16,848 abstain.","Approximately 63.18% of outstanding shares (22.7M of 35.99M) represented at meeting, constituting quorum."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-262264","json":"https://secwatch.observer/filing/0001193125-26-262264.json","markdown":"https://secwatch.observer/filing/0001193125-26-262264.md","text":"https://secwatch.observer/filing/0001193125-26-262264.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526262264/0001193125-26-262264-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526262264/antx-20260603.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T10:08:21.466256+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"15ab8c8623929e0867afc52b6d4775596c9657ec","claim":"AN2 Therapeutics, Inc. shareholders approved Ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-03 meeting.","evidence_excerpt":"2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results were as follows: Votes For Votes Against Abstentions 22,724,674 13 16,848","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526262264/0001193125-26-262264-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-03"}],"fact_type":"shareholder_vote"},{"claim_id":"bb9a31ebf98e345cdeecac82e367e89a79f759c8","claim":"AN2 Therapeutics, Inc. shareholders approved Election of the nominees Kabeer Aziz, Gilbert Lynn Marks, M.D. and Rob Readnour, Ph.D. as Class I directors at the 2026-06-03 meeting.","evidence_excerpt":"1. To elect the nominees Kabeer Aziz, Gilbert Lynn Marks, M.D. and Rob Readnour, Ph.D. as Class I directors until the Company’s 2029 annual meeting of stockholders or until their respective successors have been elected or appointed. The voting results were as follows: Name Votes For Votes Withheld Broker Non-Votes Kabeer Aziz 13,547,536 3,958,874 5,235,125 Gilbert Lynn Marks, M.D. 15,947,854 1,558,556 5,235,125 Rob Readnour, Ph.D. 15,920,563 1,585,847 5,235,125","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526262264/0001193125-26-262264-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-03"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}